Rezolute, Inc.
rezolutebio.comWhat Do They Do?
Develops ersodetug, a potential therapy for patients with hard-to-treat low blood sugar caused by hyperinsulinism.
10-K for FY2026, filed Sep 24, 2026
How Do They Make Money?
No revenue reported yet.
10-K for FY2026, filed Sep 24, 2026
How Are They Changing?
Focus on hyperinsulinism
The older report described an oral drug candidate for diabetic eye disease alongside its congenital HI candidate; the latest describes development focused on ersodetug for congenital and tumor-related HI.
10-K for FY2023, filed Sep 14, 2023 10-K for FY2026, filed Sep 24, 2026Rezolute, Inc. (“Rezolute”, the “Company”, “we” or “us”) is a late-stage rare disease company focused on developing therapies that treat…View ↗
Ersodetug for Tumor HIView ↗
Our focus as a Company is advancing ersodetug as a potential treatment for refractory hypoglycemia caused by all forms of HI, specifically…View ↗
Who Do They Compete With?
Competes with Amylyx Pharmaceuticals, Hanmi Pharmaceuticals, and Zealand Pharma
10-K for FY2026, filed Sep 24, 2026There are other companies developing therapies for HI that are potential competitors to ersodetug, including, Amylyx Pharmaceuticals, Hanmi…View ↗
Loading...
